Since the 1st of July 2023, the Belgian “National Medicines Verification System” (NMVS) is connected to the “European Alert Management System” (EAMS) via a “National Alert Management System” (NAMS).

A real-time treatment of the EU FMD alerts in the pharmacy and wholesaler software is now possible, and the Belgian NCA (FAGG -AFMPS) therefore decided to switch to a full implementation of the EU-FMD within a few months.

Given the significant impact of this measure, we strongly recommend you to register for this informative webinar that we organize for employees of organizations with a MAH licence. (duration of Webinar is 60 minutes)

webinar 10th October 11 am CET

webinar 12th October 11 am CET



  • Load CORRECT data for all serialized packs before they are distributed in the supply chain. 
    Correct means that all data, including the expiry date, must be 100% the same as the data in the 2D matrix code.
  • Communicate immediately the relation GTIN-CNK (national code for BE) for each product on the market in Belgium to the APB to avoid supply chain issues. Although FMD packs are carrying the GTIN, the entire supply chain is still mainly operating with the CNK. 
    Communication is done to

Recall instructions 

The delegated regulation states that a batch subject to recall or a product subject to withdraw should be decommissioned in the EMVS system for the affected markets. Usage of recall and withdrawal functionalities in the EMVS can further improve security in the medicine distribution by preventing that recalled or withdrawn packs are dispensed to patients. Read more 



Each Marketing Authorisation Holder, responsible for products that are in scope for FMD in Belgium and which are commercialised in Belgium, needs to register and enter into a contractual agreement with BeMVO.

 SCOPE of FMD in Belgium

This table explains the overall principle of the FMD scope for Belgium: Scope_table
For a detailed verification by product/pack we refer also to the product database managed by the Medicines Agency (FAGG/AFMPS) 
Selecting the concerned pack indicates with a flag if the concerned pack is in FMD scope or not for Belgium.

 Registration AGREEMENT

The registration agreement is composed of two documents:
The agreement : agreement operational phase
Please also provide a proof of mandate for the undersigner of the contract

The identification form : [download form]
When completed, the documents need to be sent to:


The participation fee is composed of a one-time registration fee and an annual fee. The annual fee is reviewed each year and communicated to the MAHs in the fourth quarter of the preceding year.


The one-time registration fee is set to € 10.000.


There are 3 annual fee categories, depending on the turnover of the MAH for the products in scope.

The base level of 3 categories are € 8 000, € 5 000 and € 2 000. However, each year, the level of the fee for each of the categories is reviewed in function of the financing needs of the BeMVO.

The current defined cut-off points for the 3 categories are:

Flat Fee level



2023 Fee

Standard Flat Fee

8.000,00 €


€  6 000,00

Reduced Fee




TO < 1mln Euro

5.000,00 €


€ 3 750,00

TO < 100.000 Euro

2.000,00 €


€ 1 500,00

Turnover is defined as:

The total sales value realized in Year-2 for the products belonging to the MAH and that are in FMD scope in the year on which the annual fee is applicable.
Example: the annual fee category for 2023 is decided based on the FMD products belonging to the MAH in January 2023 and on the turnover for these products in 2021 (even if these products did not belong to the MAH at that time).


  • The MAH must take the initiative and request to be eligible for a reduced annual flat fee
  • The MAH must bring sufficient proof of the lower turnover for the products in scope.
  • Such proof can consist of the following elements (not exhaustive list): official financial accounts, reports from a company auditor, external market measurement data, … 
    The documentation needs in each case to include the list of Medicinal Products that have been considered in this regard.
  • The request for a reduced fee must be provided to BeMVO latest by January 10th.
  • BeMVO can request at any moment additional information.
  • BeMVO reserves the right to reject the request at its own discretion, independent of the elements and information that has been provided by the MAH.


Although Belgium and Luxembourg share the same National Medicines Verification System (NMVS) managed by BeMVO, the governance for Luxembourg is managed by the LMVO (Luxembourg Medicines Verification Organisation).

The registration and annual fee covers only the part for Belgium. In case the MAH is also active on the market in Luxembourg (or only in Luxembourg and not Belgium), the MAH should get into an agreement with the LMVO.

For the technical side, you can find herewith the loading instructions to the Belgian NMVS for packs on the market in Luxembourg:BE-LU-data-loading-specs-LMVO-V2.1